PH KOREA 2026

Speakers

Luncheon Session 1 - Johnson & Johnson

Dae-Hee Kim

Ulsan Univ., Korea

L1-1. The Role of OPSYNVI® in PAH treatment goals : From Early risk reduction to Sustained low‑risk status

CV

Jung Hyun Choi

Pusan National Univ., Korea

L1-2. Clinical Efficacy of OPSYNVI® Compared with Monotherapy : Clinical evidence and Real-world practice in PAH

Luncheon Session 2 - Bayer (Korean)

손정우

연세의대 심장내과

L2-1. Unlocking the potential of PAH management w/ Riociguat

이재승

울산의대 호흡기내과

L2-2. Establishing CTEPH standard of care

CV

Luncheon Session 3 - MSD

Jung Hyun Choi

Pusan National Univ., Korea

L3-1. The First Activin Signal Inhibitor, Sotatercept

Nick H. Kim

UCSD, USA

L3-2. Learnings from Real World Experience of Sotatercept

CV

Luncheon Session 4 - Celltrion Pharm.&Chong Kun Dang (Korean)

정중화

조선의대 순환기내과

L4-1. Beta blocker use in Hypertension : Old & New Sight

CV

김경희

인천세종병원 심장내과

L4-2. How is Carvedilol different from other beta blockers : β-blockers & Beyond

CV

Session P9 - Industrial Session; All About Activin Signaling Pathway

Dae-Hee Kim

Ulsan Univ., Korea

P9-1. Sotatercept for Patients Not Reaching Low Risk

CV

John Feenstra

The Wesley Hospital, Australia

P9-2. Paradigm Shift in PAH Treatment and Role of Sotatercept

CV

Soo Yong Lee

Pusan National Univ., Korea

P9-3. Sotatercept Position in Guidelines and How Does It Really Work

Jina Yeo

Gachon Univ., Korea

P9-4. Who Would Benefit from ASI / Sotatercept in Korea? (Deep dive into CTD-PAH)

CV
X
X
X
X
X
X
X
X